Half-yearly review of the ABL Diagnostics Liquidity Contract in 2026

ABL Diagnostics has published its liquidity contract report for the first half of 2026. As of June 30, 2026, the liquidity account held 33,993 shares of the company and €76,654.75. During this period, 106,097 shares were purchased for a total of €355,665.92, while 116,652 shares were sold for €415,860.90. At the end of 2025, the account held 44,548 shares and €16,167.24. Since the contract's inception in April 2024, the initial holdings were 10,000 shares and €30,000. The liquidity contract, designed to stabilize the share price, reflects the active trading activity of ABL Diagnostics shares.